Comorbidities in interstitial lung diseases
release_hjrhoiesqvhf5e5gyh2k4myx6q
by
George A. Margaritopoulos, Katerina M. Antoniou, Athol U. Wells
2017 Volume 26, Issue 143, p160027
Abstract
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.
In text/plain
format
Archived Files and Locations
application/pdf 351.9 kB
file_yg7kmst5zbhsnn34ctihljbhsi
|
web.archive.org (webarchive) err.ersjournals.com (web) |
application/pdf 351.9 kB
file_maoj2odl6nchphkwtarlysd2yq
|
web.archive.org (webarchive) err.ersjournals.com:80 (web) |
Web Captures
https://err.ersjournals.com/content/26/143/160027.full
2020-08-14 04:53:58 | 51 resources webcapture_ufbg6khtmbgwpavp5p4nocrwsa
|
web.archive.org (webarchive) |
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:
0905-9180
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar